The gratifying results of lung transplantation in terms of survival and quality of life stimulate the referral of an ever-increasing number of patients with end-stage lung disease. This in turn compounds the organ shortage, which is the limiting factor in the transplantation rate. In the absence of good alternative treatment modalities, an evidence-based pretransplant screening process is a prerequisite to detennine which patients will benefit most from transplantation. Within this evidence-based screening process, medical selection criteria are well established. There is a growing awareness that psychosocial and behavioural factors may determine outcome after transplantation as well. This paper reviews the available evidence for psychosocial and behavioural factors in the screening process for lung transplantation. The relation of various factors with post-transplant outcome was explored. Psychosocial characteristics before transplantation consist of 1) anxiety and depression, 2) personality disorders, 3) neurocognitive problems, and 4) lack of social support. Pretransplant behavioural factors include 1) noncompliance with medication, 2) alcohol abuse or dependence, 3) smoking, 4) noncompliance with dietary guidelines, and 5) noncompliance with monitoring of vital parameters and infections. It appears that the lack of rigorous studies limit the feasibility of an evidence-based screening process. Prospective studies are crucial to this further investigation of the relationship between psychosocial and behavioural determinants before transplantation and outcomes after transplantation, in terms of compliance, morbidity, and mortality. Identification of modifiable risk factors for poor outcome before transplantation is a first step in developing interventions. Chronic Respiratory Disease 2006; 3: 39-47 Psychosocial and behavioural factors before lung transplantation F Dobbels et al.
Introduction
The first successful single lung transplantation was performed in Toronto in 1983.1 Since then, improvements in organ preservation methods, surgical techniques, immunosuppressive medications, posttransplant care and long-term management have resulted in an increased life expectancy after single and bilateral lung transplantation.2 6 Actuarial survival at one, five and 10 years after transplantation in 2002 was 74%, 47% and 24%, respectively, which is much better than what is to be expected in patients with end-stage lung disease without transplantation. The global conditional half-life was 6.9 years, with a significantly higher halflife for bilateral lung transplantation compared to single lung transplantation due to differences in operation procedure, age and aetiology of end-stage lung disease (i.e., 8 .3 years versus 6.2 years, respectively).7 Longterm survival is expected to further increase in the next decade.
Due to these successes and more liberal selection criteria, an increasing number of patients with endstage lung diseases are referred for evaluation for lung transplantation. End-stage lung disease may result from a variety of underlying diseases typical for specific age spans, including suppurative, obstructive, restrictive and vascular pulmonary disease,4'8'9 making lung transplant candidates a very heterogeneous group. Currently, the four main indications for lung transplantation are chronic obstructive pulmonary disease (COPD, 39%: typically patients in their sixth decade), idiopathic pulmonary fibrosis (IPF, 17%: mostly patients in their fourth decade), cystic fibrosis (CF, 16%: patients in their second or third decade) and a1antitrypsin deficiency emphysema (9%: patients in their fourth or fifty decade). 7 In contrast to heart and liver transplantation, lung transplantation is rarely an option for acutely, critically ill patients.10
Organ shortage, however, continues to limit the number of transplantations performed.' 1'12 The imbalance between the number of potential donors and the number of available organs causes an increase of waiting times and consequently, mortality on the waiting list.11',3 In a European study, 25% of patients died on the waiting list during a two-year time period. '4 Similarly, one-year mortality on the waiting list in the USA was 11%. 10 It is thus of utmost importance to determine which patients have the greatest benefit from transplantation. '5"16 Medical selection criteria are well established: in 1998, an international panel of experts from the International Society for Heart and Lung Transplantation, the American Society for Transplant Physicians, the American Thoracic Society, the European Transplant Society and the Thoracic Society of Australia and New Zealand agreed upon a set of guidelines,'0 that were recently updated." 1 This medical selection process is briefly summarized below.
There is growing awareness that a number of psychosocial and behavioural issues, in addition to medical factors, will affect the success of transplantation as well. The aim ofthe present review is therefore to summarize the available evidence regarding pretransplant psychosocial and behavioural screening factors for lung transplantation.
Medical issues in pretransplant screening
The process of transplant candidate selection usually involves two major steps: The assessment of the indication for transplantation and screening for contraindications.
In the first phase, it should be demonstrated that no other pharmacological or surgical options are available to treat the end-stage lung disease.)0 Further, estimates concerning expected outcomes should be made. Life expectancy without lung transplantation is usually limited to two to three years, which represents the upper limit of the mean waiting time before transplantation.4'117 Based on the International Society for Heart and Lung Transplantation Thoracic Registry data, North-American patients with pulmonary emphysema seem to form an exception to this rule: the relative mortality risk after lung transplantation up Chronic Respiratory Disease to one year after transplantation did not decline below the risk of continued waiting on the pre-transplant waiting list.7 Data from the Eurotransplant Registry, however, show that lung transplantation benefited survival in patients with pulmonary emphysema.14 Consequently, lung transplantation should be viewed as a valuable option for pulmonary emphysema both in terms of quality and quantity of life. '8'19 In addition to a limited life expectancy, a lung transplant candidate should have a severely limited functional status (New York Heart Association Classification Class III or IV).4'8" H The ultimate goal is to list a patient when the disease is severe enough to warrant transplantation, yet, while the patient is well enough to survive the waiting time until transplantation.8 This time period is often called 'the transplant window'.
The second phase of the medical screening process before transplantation refers to the screening for potential contra-indications. There are absolute and relative contra-indications. Absolute medical contraindications are co-morbid conditions that may be exacerbated by the process of transplantation or by the immunosuppressive regimen after transplantation, and consequently may have an impact on clinical outcomes after transplantation. Older age (> 65 years), infectious disease (e.g., AIDS), malignancy (less than two years disease free time), systemic disease, cardiovascular and cerebro-vascular diseases are absolute contraindications in most lung transplant centres.10"' Diabetes is a relative contra-indication and patients with diabetes mellitus should be screened carefully to assess the degree of end-organ damage, such as retinopathy, peripheral neuropathy and diabetic foot disease. If cardiac, liver or renal disease is present, the severity and reversibility of these disease conditions should be assessed first in view of patient's suitability for transplantation.
Psychosocial and behavioural issues in pretransplant screening
There is growing awareness that the psychosocial and behavioural issues, in addition to typical medical factors, will also affect the ultimate success of transplantation. As a consequence, most guidelines state that careful screening before transplantation is not limited to comprehensive medical evaluation, but should also involve a thorough psychological assess- 20 24 ment.
Active substance abuse or dependence is an absolute contra-indication for lung transplantation. Candidates for lung transplantation must have been free of substance addiction (i.e., alcohol, tobacco, and narcotics) for at least six months.1022 In addition, poorly controlled psychoaffective disorders (i.e., anxiety and depression), inability to understand and cope with the complexity of the therapy or to comply with medical recommendations, poor social support in conjunction with an inability or unwillingness to develop a working relationship with the transplant team are relative contra-indications for lung transplantation.8101125 Whereas assessment for the medical selection criteria is well established, the assessment of psychosocial and behavioural criteria is less straightforward. First, it is unclear which psychosocial and behavioural factors predict poor outcome after transplantation. Prospective studies quantifying the prognostic value of pretransplant psychosocial and behavioural factors in lung transplantation are scarce, limiting the feasibility of an evidence-based pretransplant psychosocial and behavioural screening protocol.2627 Secondly, a standardized assessment of these factors does not exist.
The current review summarizes the available evidence regarding pretransplant psychosocial and behavioural screening factors for lung transplantation. The review will expand our previous work in heart, liver and renal transplantation to the field of lung transplantation, using the same conceptual framework.28 Based on this literature review, the following psychosocial factors were deemed to be relevant: 1) anxiety and depression, 2) personality disorders, 3) neurocognitive problems, and 4) lack of social support. Behavioural factors explored in lung transplant candidates refer to 1) noncompliance with medication taking, 2) alcohol related problems, 3) smoking, 4) noncompliance with dietary guidelines, and 5) noncompliance with monitoring of vital parameters.
The impact of these factors on post-transplant outcome will be investigated, in view of survival and morbidity, as well as in view of psychosocial, behavioural and quality of life outcomes after transplantation.29 '30 The databases Pubmed, Psychlit and Cinahl were reviewed for relevant articles published between 1986 and 1 August 2004. The following search terms were used separately and in combination: 'lung transplant*': 'psych*', 'psychosoc*', ' anxi*', 'depress*' 'distress', 'personality', 'social', 'support', 'complian*', 'noncomplian*', 'adheren*', 'nonadheren*', 'smoking', 'alcohol', 'addict*', 'diet*', 'vital parameter*', 'monitoring', 'neurocognitive', 'cognit*', 'memory', 'concentr*', 'pretransplant screening', 'selection', 'quality of life'. The selection of articles for this review was based on revision of the abstracts. The reference lists of the retrieved articles were also reviewed for additional publications.
The most important findings of this literature search for each behavioural and psychosocial factor are presented below.
Psychosocial screening factors
Psychological factors before transplantation encompass depression and anxiety, personality disorders, neurocognitive disorders and lack of social support.
Depression
Since the period before transplantation is flawed with uncertainty and concerns about the future, it is not surprising that lung transplant candidates may experience anxiety and depression.31 Table 1 summarizes the prevalence of depressive symptoms in lung transplant candidates.
Overall, between 0% and 48% of candidates show mild to severe depressive symptoms, depending on definition and measurement method used.20 27'32 35 The weighted mean over all publications for presence of depressive symptoms was 29.5%. Transplant candidates experienced a significantly higher level of depression than was found in normative nonmedical community samples (i.e., a point prevalence of 5% to 9% for women, and 2% to 3% for men, respectively). On the other hand, the prevalence of depression in transplant candidates was comparable to the prevalence rate in other chronic disease populations. [36] [37] [38] The prevalence is fairly similar for the different indications for transplantation.32
Considering the relationship between depression and outcome, two studies showed that depression was not a significant predictor of survival both before and after transplantation.3'39 Surprisingly, Woodman et al. 27 found that patients with a history of depression or www.CRDjournal.com anxiety were more likely to survive after transplantation. The authors proposed that these patients are better prepared to identify and cope with psychosocial difficulties. Yet, this hypothesis needs to be tested in larger-sample, multicentre prospective studies. Depression before transplantation was also not associated with number of infections, rejections, or development of bronchiolitis obliterans syndrome (BOS).3 However, higher levels of depressive symptoms before transplantation (as measured by the Beck Depression Inventory) were associated with increased subjective sleep disturbances after transplantation, poorer mental health and more cardiovascular and pulmonary symptoms (after controlling for pre-, and post-transplant physical health).3 A history of a depressive disorder (i.e., depression unrelated to the pretransplant phase) seems to be an important risk factor for both pre-and post-transplant psychological distress,24,35,40 and should therefore be carefully screened for during the pretransplant evaluation.
Although the prevalence of depression generally decreases after transplantation (e.g., prevalence decreases from 25% before transplantation to 8% after transplantation in the study of Limbos et al. 34 ), the prevalence remains higher than in the general population (i.e., a point prevalence of 5% to 9% for women, and 2% to 3% for men, respectively). Yet, the number of longitudinal studies is limited.34'4' Depressive symptoms tend to increase with longer time since 41, 42 transplantation.
The declined psychological functioning (around three years post-transplant) in the study of Vermeulen et al.41 may be explained by an increase in co-morbid conditions in the long-term after transplantation (e.g., diabetes mellitus, decrease in kidney function, Bronchiolitis Obliterans Syndrome) and repeated hospital admissions.
Anxietv
Anxiety and panic related episodes might frequently occur before transplantation and result from biological (i.e., increased PaCO2 levels) or psychological factors associated with the stress of having a debilitating illness.20 The prevalence of anxiety during the pretransplant phase ranges between 8% and 51% (see Table 2 ), depending on case finding and measurement methods used.20 '27'32-35 The weighted mean for anxiety symptoms is 29.3%, which is high compared to the prevalence found in the general population (i.e., 1-13%)*43-45 Timing of assessment may also play a role. Relatively low anxiety levels can be expected in the initial phase of the pretransplant process, as patients are relieved of being accepted on the transplant waiting list. However, the prolonged waiting time may stimulate anxiety. 46 observed that patients with cystic fibrosis (CF) reported lower levels of anxiety than patients without CF, even after controlling for age. Further research is needed to compare the prevalence of anxiety among different forms of end-stage lung disease.
Anxiety before transplantation was associated with poorer functional and emotional quality of life after transplantation. Higher levels of pretransplant anxiety were also associated with increased subjective sleep disturbances, anxiety, and post-transplant cardiovascular and pulmonary symptoms.3'6 Thus, good adjustment before transplantation is predictive for good adjustment and quality of life after transplantation, irrespective of disease status. 3, 6, 47 Most studies report a decreased anxiety level in the early period after transplantation.3'34'46 ' 49 A lower prevalence compared to the period before transplantation was also found in the long-term follow-up after transplantation (up to 19 months in the longitudinal study of Ten Vergert et al. 46 ).
Personality disorders
A personality disorder is a cluster of persistent symptomsincluding severe disturbances in emotions, social contacts, behaviour and/or impulse controlwith an onset in adolescence or early adulthood (between 15 and 25 gears of age) and persisting during the whole lifetime.37,50 Studies regarding personality functioning and disorders are limited in lung transplant patients, as well as in other transplant candidates and are usually case reports or small sample studies.
Chesler et al.51 reported on an adult male patient
who developed an eating disorder while trying to qualify for lung transplantation. In the study of Singer and colleagues,52 four percent of candidates for lung transplantation showed signs of possible antisocial personality. This longstanding pattern of personality dysfunction may be exaggerated by the stress of a lifethreatening disease and may impact on noncompliance.52 However, the presence and impact of pretransplant personality disorders on post-transplant outcome has not been explored in lung or other transplant populations. Active cooperation regarding the post-transplant regimen may be jeopardized in patients with a personality disorder because of the long-standing patterns of social, behavioural or emotional dysfunction. So far, pharmacological and psychotherapeutic interventions have shown limited effectiveness in patients with personality disorders. Given the limited evidence for the management of these patients, more research is required to explore the relationship between personality functioning, noncompliance and outcome.
Neurocognitive functioning
One of the factors also influencing compliance is neurocognitive functioning. Neurocognitive evaluation is helpful to detect problems with memory and concentration that might jeopardize patients' capacities for selfmanagement or compliance to the complex treatment regimen after transplantation.53 Although some evidence is available in patients with chronic obstructive lung disease (COPD),54'55 the number of studies examining the neurocognitive functions in lung transplant candidates is limited. Crews et al. 53 showed that patients with end-stage lung disease have an impaired processing abilities and auditory-verbal and visual memory, including also a deficit in immediate free recall, longterm storage and retrieval strategies. Arterial hypoxia and hypercapnea secondary to ineffective gas exchange, and co-morbid conditions such as vascular disease and psychological distress may explain this impairment in neurocognitive functioning.53
Pretransplant oxygen therapy ma4y improve cognitive function before transplantation.56 No data are available to substantiate the reversibility of neurocognitive functioning after lung transplantation. Importantly, the post-transplant immunosuppressive regimen itself may also affect neurocognitive functioning, as cyclosporine and tacrolimus cause a variety of central nervous system effects in approximately 10-40% of lung transplant recipients, ranging from tremors, paresthesias, headaches, seizures, ataxia, difficulty with speech, cortical blindness tovery rarelycoma.57 '58 The toxicity of cyclosporine and tacrolimus is very similar. Their adverse neurocognitive effects are exacerbated in the presence of hypertension, hypercholesterolemia, and low magnesium levels.57'58 Lowering the dose or switching to another, less neurotoxic immunosuppressive drug regimen may reverse these neurocognitive symptoms. Prospective studies exploring the relation between pretransplant factors, lung transplantation and immunosuppressive treatment on recovery of pretransplant neurocognitive deficits, however, are currently lacking.
Lack ofsocial support
Presence of family and friend support is stated as crucial for listing on the lung transplant waiting list in the lung transplant literature. , 12, 20 Social support refers to the verbal as well as nonverbal exchanges during interpersonal transactions.59 Two major categories of social support can be distinguished, i.e., perceived and received social support. Both have specific effects on health, well-being and health behaviour.59 '60 Perceived social support refers to a patient's perception of the available support in case the patient needs it. High levels ofperceived social support seem to have stress buffering capacities. Patients with low perceived social support are therefore more likely to develop depression or anxiety in both transplant and non-transplant populations.6'-63
Received social support refers to the actual received infonnational, instrumental, tangible, emotional and appraisal support. Higher levels of received social support have been linked to better patient compliance.60'6466Received social support refers for instance to the caregiver preparing patient's meals, reminding patients of medication intake, and redeeming prescriptions at the pharmacy. Thus, patients with an empathic and supportive partner have significantly better surgical and outcomes after transplantation compared to patients without a supportive partner. 26'67'68 Perceived and received social support are thus relevant parameters to address during the pretransplant selection process, because ofthe proven stress buffering mechanisms in view of development of anxiety and depression on the one hand, and compliance behaviour on the other hand. However, no studies have been performed so far in lung transplant candidates showing the beneficial effects of social support on outcome after transplantation. The limited number of studies exploring social network factors and their function in candidates for lung transplantation calls for more work in this area. Support can be modified, and interventions aimed at increasing social support will probably feature as an important way of improving outcome in transplant patients.
Behavioral factors
Behavioural factors refer to compliance with the therapeutic regimen, including regular intake of medication, smoking cessation, following guidelines www.CRDjournaI.com with respect to alcohol use and diet, and monitoring of vital parameters (e.g., spirometry) and infection.
Medication noncompliance
To date, no studies on medication noncompliance before transplantation have been published. Based on evidence from other chronic disease populations showing that previous noncompliance is a good guide to current and future noncompliance, the relevance of pretransplant noncompliance as a predictor for post-transplant medication noncompliance can be assumed. 69 Only two studies have investigated post-transplant noncompliance with the immunosuppressive medication after lung transplantation. Prevalence of medication noncompliance after transplantation as assessed by self-report70 was 22.5%. The majority of these patients (19.5%) reported that they forgot their medication once a month, and 3% said they forgot it twice monthly. Matthees et al.,71 also using self-report measures, found that the prevalence of noncompliance ranged from 2-34.7%, depending on the question asked: 1) Do you ever forget to take your medication? (34.7%); 2) Are you careless at times about taking your medicine? (12.1%); 3) When you feel better, do you sometimes stop taking your medication? (2%); 4) sometimes when you feel worse when you take your medicine, do you stop taking it?
Noncompliance with immunosuppressive drugs in heart and renal transplantation has been shown to be an important risk factor for poor outcomes in terms of graft loss and late acute rejections.72 7 Lung transplant patients receive a more intensive immunosuppressive therapy than heart, liver or kidney transplant patients. Future studies should include the use of electronic monitoring as a more reliable measure to substantiate the prevalence of noncompliance and discuss the effect of noncompliance on outcome in lung transplant recipients. In addition, research in heart and lung transplantation showed that post-transplant noncompliance with the immunosuppressive regimen is predictive for poor clinical outcome in terms of late acute rejection and graft loss. Evidence in lung transplant populations, however, is currently lacking. Future studies should focus on the impact of pretransplant noncompliance on post-transplant noncompliance to drug therapy and subsequent clinical outcome.
Alcohol abuse or dependence
According to the DSM-IV psychiatric classification system,37 alcohol abuse is defined as the physical dependence, manifested by tolerance to ethanol, together with the inability to control the alcohol use Chronic Respiratory Disease or to sustain efforts to cut down the drinking behaviour. This may result in disrupted social or physical functioning. 37.76 To our knowledge, no publications exist regarding prevalence of alcohol abuse/dependence in patients being screened or accepted for lung transplantation. As for other types of transplantation, it is unclear to which extent severity and duration of alcohol abuse or the time of abstinence predicts outcome after transplantation. In liver transplant recipients, relapse rate for patients transplanted for alcoholic cirrhosis ranges between 15 and 25%. 77 Alcoholics are at risk from poly-substance abuse such as the combined use of tobacco and illicit drugs, both known risk factors for poor outcome after transplantation.77 Alcohol abuse is also more prevalent in some major psychiatric diagnoses (e.g., schizophrenia and depressive disorder) and personality disorders (e.g., borderline and antisocial personality disorder).7 -l A long period of heavy drinking can also result in Wemicke's encephalopathy, which is characterized by irreversible intellectual and neurocognitive dysfunction.37'82 Because irreversible brain damage limits the ability to assimilate new information, and because alcoholism is associated with a lack of self-care, the likelihood of poor post-transplant noncompliance may be higher in this patient group.
However, the negative consequences of alcoholism on compliance and subsequent outcome can only be inferred from the above-mentioned observations. Conclusive data on the relationship between pretransplant alcohol (ab)use and post-transplant noncompliance are lacking at present in lung and other transplant patients. The prevalence and impact of noncompliance with pretransplant alcohol guidelines on post-transplant outcome should be substantiated in lung transplant candidates.
Noncompliance with smoking cessation
Patients should refrain from smoking both before and after transplantation, because smoking after transplantation in combination with immunosuppressive medication is associated with malignancy, cardiovascular events and mortality in other transplant populations.83'84 There are no studies reporting on the rate of smoking cessation in patients being screened or accepted fur lung transplantation. Since patients who did not quit smoking are excluded from listing for transplantation, this lack of information may not be surprising. l 0' I I Limited evidence shows that 20-40% of heart transplant candidates restart smoking after transplantation.83 The prevalence of smoking relapse after lung transplantation in former or current pretransplant smokers remains unknown. It would be worthwhile to ascertain smoking rates in lung transplant candidates and transplanted patients in order to assess whether smoking-cessation interventions are needed.
Noncompliance with dietary guidelines
Obesity is regarded as an indirect marker of noncompliance with dietary guidelines. Obesity is defined as a body mass index (BMI) of more than 30 kg/M2. Morbid obesit is characterized by a BMI higher than 35 kg/m ). Obesity is associated with periand postoperative cardiac, pulmonary, endocrine and gastrointestinal dysfunction in many types of surgical procedures, including transplantation.85 -88 Obesity seems not to occur frequently in candidates for lung transplantation (i.e., less than 2% of candidates according to a personal communication with Prof. Dupont). However, research in transplant patients is limited and data assessing compliance with diet in lung transplant candidates are not available. Based on research findings from other types of transplantations, obese patients may need to lose weight before transplantation. Also, patients should be carefully screened for cardiac morbidity before transplantation, in order to modify the detrimental impact of obesity and high cholesterol levels on post-transplant outcome.
Monitoring of vital parameters
Self-monitoring of vital signs and symptoms is an essential aspect of adequate patient self-management. Monitoring parameters of health status on a regular base (e.g., blood pressure, weight, pulse, sputum amount and colour) may result in a better communication between the pretransplant patient with a precarious health and the transplant team, and may result in earlier detection of health problems that could easily be treated. 89 Only one study assessed pretransplant noncompliance with monitoring vital parameters.89 This study used an electronic diary to collect a range of health related measures and symptoms (e.g., sputum amount and colour, shortness of breath at rest and during exercise, and hours spent in bed), to assess the need of treatment (oxygen usage, antibiotics, prednisone dosage, hospitalizations and physician visits) and quality of life. Subjects were considered to be nonadherent if they transmitted data less than once a month, resulting in a noncompliance prevalence of 28% in 57 patients. 89 Compliance with spirometry in the post-transplant phase has been extensively studied. Monitoring of lung function with a portable spirometer in lung transplant patients has proved to be a valuable alternative for more invasive screening procedures for infection and rejection including the examination of transbronchial lung biopsies and bronchoalveolar lavage fluid. Although noncompliance to home spirometry is not life threatening, it is imperative that patients monitor lung function on a regular basis to detect changes in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) indicative of infection or rejection, as many patients remain asymptomatic until severe sepsis or respiratory failure occurs.909 The prevalence rate of noncompliance varies according to the definition of noncompliance used and the number of data transfers required. The prevalence ranges between 15 and 45%.91 -96 Reasons for noncompliance in the study of Sabati et al.95 were: laziness, unavailability of equipment or supplies, forgetfulness, time conflict, feeling sick, feeling healthy, travel, no perceived benefits, and out of habit. Interestingly, compliance is higher when the patient is instructed to perform one measurement session a day versus two measurement sessions (i.e., 85% versus 55% compliance in the study of Morlion et al. 96 ). This is in accordance with the results of the meta-analysis of Claxton et al., 97 showing that a higher number of medication dosages per day are related to medication non-compliance. Moreover, compliance tended to decrease over time.92 Therefore, Lindgren and colleagues94 suggest continuous encouragement and feedback in combination with other compliance interventions to enhance successful lung function measurement. Interventions include telephone calls if patients had not been transmitting data, meetings with the nurse during clinic visits, a personalized graph of health status, a newsletter that provides reminders and tips.94
Conclusion
This paper has reviewed the relevance of psychosocial and behavioural factors in the transplant screening process for lung transplant candidates. The importance of the different factors relevant to successful outcome after transplantation has been explored. The lack of rigorous studies, both in lung and other transplant domains28 limits the development of an evidencebased screening process for organ transplantation. Prospective studies are necessary to explore the relationship between psychosocial and behavioural pretransplant determinants and post-transplant outcomes, in terms of compliance, morbidity, and mortality. Identification of modifiable pretransplant risk factors for poor outcome is a first step for developing these interventions.
